Physician profile
Beth A Wimer
NPI 1932189941
$10,211.75
in general payments reported to CMS, 2019-2025
32 companies · $3,423 in 2025
The $3,423 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,271 · 2022: $1,479 · 2023: $1,718 · 2024: $2,321 · 2025: $3,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,323 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,322.63 |
| Education | $139.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,690.82 | 2021-2025 | |
| Janssen Biotech, INC. | $1,834.10 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,410.15 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $530.29 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $379.38 | 2022-2025 | Dupixent |
| Pfizer INC. | $353.55 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $202.67 | 2023-2024 | Rebyota, Clenpiq |
| Phathom Pharmaceuticals, INC. | $193.86 | 2025 | Voquezna |
| Genzyme Corporation | $191.62 | 2022-2025 | |
| Qol Medical, LLC | $167.35 | 2021-2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $154.85 | 2024-2025 | Iqirvo, Bylvay |
| Celltrion USA INC. | $151.16 | 2024-2025 | Zymfentra, Vegzelma |
| Ardelyx, INC. | $140.27 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $137.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $85.67 | 2024-2025 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $78.45 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $66.73 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $55.01 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $48.80 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.40 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $44.22 | 2021-2022 | |
| Vifor Pharma, INC. | $39.44 | 2021-2022 | |
| Daiichi Sankyo INC. | $38.08 | 2021-2023 | Injectafer |
| Gilead Sciences, INC. | $33.86 | 2021-2024 | |
| Exact Sciences Corporation | $23.17 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $19.59 | 2025 | Interstim |
| Braintree Laboratories, INC. | $18.17 | 2022 | |
| Merck Sharp & Dohme LLC | $17.75 | 2024 | Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $15.71 | 2025 | |
| Alfasigma USA, INC. | $14.25 | 2022 | |
| Sandoz INC. | $13.85 | 2024 | Hyrimoz |
| Celgene Corporation | $13.37 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Wimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.